百家乐怎么玩-澳门百家乐官网娱乐城网址_网上百家乐是不是真的_全讯网888 (中国)·官方网站

Recent advances in the synthesis, stability, and activation of platinum(IV) anticancer prodrugs
20210518_1.jpeg

Published on Angewandte Chemie (18 May 2021)

 

Author(s): Zoufeng Xu, Zhigang Wang, Zhiqin Deng, Guangyu Zhu*

 

Abstract

Platinum-based anticancer drugs have been widely applied in clinical settings for more than 40 years. The remarkable breakthroughs that have come from the use of these complexes in cancer therapy have stimulated a continual search for new platinum anticancer drugs. The most promising result of these efforts is a prodrug strategy based on the use of platinum(IV) versions of the traditional platinum(II) anticancer drugs. Hence, the design of synthetic methods for platinum(IV) prodrugs and an understanding of their hydrolytic stability and intracellular activation processes are critical for the development of platinum(IV) prodrugs for cancer therapy. In this review, we summarize recent progress in this field from a comprehensive viewpoint, with an emphasis first on the oxidation processes in chemical environments where platinum(II) compounds are converted to their platinum(IV) species, followed by the reduction processes in biological environments where platinum(IV) species are converted back to platinum(II) forms. First, recent approaches that use new oxidizing reagents to synthesize platinum(IV) prodrugs are summarized, and the oxidation mechanisms and outer-sphere functionalization of platinum(IV) prodrugs are examined. Second, the hydrolysis of platinum(IV) complexes, which has sometimes been underexplored, is discussed, and the factors associated with the hydrolytic stability of platinum(IV) complexes are reviewed. Last, we focus on the reduction of platinum(IV) prodrugs, from the perspectives of reduction potential, rate of reduction, reducing agents, and reduction products. The need for new strategies to achieve controllable intracellular reduction of platinum(IV) prodrugs is emphasized. This review aims to help researchers to improve their understanding of platinum(IV) anticancer prodrugs and hopefully to generate new ideas, strategies, and applications in the area of metal-based drugs.

 

20210518_2.jpeg


Read more: https://doi.org/10.1016/j.ccr.2021.213991

 

 

background
 
 
 
 
 
 
 
 
澳门博彩业| 百家乐官网桌台布| 大发888娱乐场c17| 全讯网3344111| 百家乐官网网站那个诚信好| 真人百家乐平台下载| 百家乐最新赌王| 百家乐透明发牌靴| 闲和庄百家乐官网的玩法技巧和规则 | 金牌百家乐官网的玩法技巧和规则 | 百家乐游戏唯一官网站| 线上百家乐玩法| 百家乐保单机作弊| 威尼斯人娱乐老品牌| 大发888娱乐城888 bg| 爱拼娱乐场| 百家乐怎样赢| 百家乐官网金币游戏| 赌场百家乐官网玩法介绍| 百家乐官网赌场娱乐城大全| 真人百家乐官网斗地主| 百家乐官网的玩法技巧和规则 | 毕节市| 百家乐官网d博彩论坛| 澳门百家乐官网下路写法| 网上百家乐官网骗人吗| 赌博百家乐官网技巧| 百家乐官网娱乐送白菜| 八卦图24山代表的| 缅甸百家乐的玩法技巧和规则 | 乐利来国际| 莱阳市| 百家乐官网庄闲收益率| 百家乐官网庄牌闲牌| 百家乐平六亿财富| 大发888游戏 平台| 德州扑克单机版| 百家乐官网注册送10彩金| 百家乐官网英皇娱乐场| 真人百家乐开户须知| 百家乐换人|